To determine the safety of single daily dose (SDD) gentamicin in recipients of stem cell transplantation (SCT), we evaluated all adult patients at MD Anderson Cancer Center who received SDD gentamicin for treatment of febrile neutropenia. Thirty-three patients received gentamicin 5 mg/kg i.v. every 24 h. Mean duration of therapy was 7 days (range 3-32 days). All patients received vancomycin and 17 received cisplatinum. All patients had normal renal function prior to therapy. Serum gentamicin levels were monitored only when renal function deteriorated. The incidence of nephrotoxicity and clinically significant ototoxicity was 3% and 12%, respectively. All four patients who developed ototoxicity had normal renal function before and during therapy. The mean duration of gentamicin therapy was significantly longer in patients who developed ototoxicity, 20 days vs 9 days (P = 0.001). Patients treated with SDD gentamicin for Ͼ10 days were more likely to develop ototoxicity (P = 0.045). Single daily dosing of gentamicin was associated with clinically significant ototoxicity in 12% of our patients. A larger randomized EORTC trial evaluating SDD vs MDD amikacin failed to detect a difference in ototoxicity. However, the median duration of therapy was only 8 days. The increased incidence of ototoxicity in our study may be due to prolonged therapy, type of aminoglycoside used, concomitant ototoxic agents, small sample size, or a combination of the above.
High-dose chemotherapy with bone marrow or peripheral blood stem cell support is increasingly used in the treatment of a variety of malignancies. 1 A major challenge to successful transplantation is the morbidity and mortality associated with infection during the neutropenic period. 2 Single daily administration of aminoglycosides is a concept that has been explored in immunocompromised patients and is gaining acceptance. 3 Single daily dose (SDD) aminoglycosides offers less frequent dosing, effective serum concentrations, Correspondence: D Warkentin, CSU Pharmaceutical Sciences, Vancouver Hospital and Health Sciences Center, 855 West 12th Avenue, Vancouver, Canada V5Z 1M9 Received 22 May 1998; accepted 26 January 1999 and reduced nursing time compared with the standard every 8 to 12 h dosing. Published clinical trials have suggested that SDD aminoglycosides in combination with other antimicrobials, are safe, effective, and potentially less toxic in febrile granulocytopenic cancer patients. [3] [4] [5] [6] [7] [8] Based on these findings, the empiric antimicrobial regimen in the febrile neutropenic stem cell transplant (SCT) patient at MD Anderson Cancer Center was changed to include gentamicin at a dose of 5 mg/kg administered over 1 h i.v. once daily for the duration of neutropenia in marrow and peripheral blood stem cell recipients. Gentamicin was chosen because it is significantly less expensive than amikacin and tobramycin and because resistance has not been noted in our institution. Several months after the institution of this new antimicrobial therapy, which included SDD gentamicin in combination with ceftazidime and vancomycin, ototoxicity was noted in several patients. This finding prompted an immediate evaluation of all patients who had received SDD gentamicin. Our objective in the retrospective review was to determine risk factors and incidence of toxicity associated with the administration of SDD gentamicin in SCT.
Patients and methods
Medical records were retrospectively reviewed for all hospitalized SCT recipients who received SDD gentamicin therapy during the first 2 months of implementation of this regimen. Treatment protocols were approved by the Institutional Review Board, and written informed consent was obtained from each patient. All febrile neutropenic patients received vancomycin 1 g i.v. over 2 h every 12 h, ceftazidime 1.5 g i.v. every 6 h and gentamicin 5 mg/kg i.v. over 1 h every 24 h. Patients who were allergic to cephalosporins received aztreonam 2 g i.v. every 8 h. Antibiotics were discontinued when the absolute neutrophil count was у1000/mm 3 and the patient was afebrile for 48 h. Patients with clinically significant otologic dysfunction were not treated with aminoglycosides. Audiograms were not routinely performed. Only those patients with normal renal function, based on serum creatinine of Ͻ110 mol/l or measured creatinine clearance of Ͼ80 ml/min at initiation of therapy, were eligible for SDD aminoglycoside administration. Aminoglycoside serum concentrations were not routinely monitored. Levels were drawn, however, when serum creatinine concentration increased Ͼ1.5 times the baseline serum creatinine concentration. Serum creatinine concentrations were monitored at least three times weekly while on therapy. The diagnosis of ototoxicity was made based on clinical signs and symptoms assessed through daily physical examinations.
For comparisons of continuous variables in patients who experienced ototoxicity vs those who did not, the Student's t-test was used. Chi-square analysis was used for categorical variables. Tests were two-tailed and P = 0.05 was considered significant.
Definitions
Fever was defined as a temperature у38.3°C on one occasion in the absence of an obvious noninfectious cause of fever, such as blood product administration. Neutropenia was defined as an absolute neutrophil count Ͻ1000/mm 3 . Nephrotoxicity was defined as a rise in serum creatinine of more than two times the baseline value during aminoglycoside therapy. Ototoxicity was observed clinically and subsequent tests were performed to determine the extent of otoxicity. Ototoxicity was defined as damage to inner-ear function, either auditory or vestibular, without any other identifiable cause.
Results
Thirty-three patients received SDD gentamicin for the treatment of febrile neutropenia. Patient characteristics are listed in Table 1 . The majority of patients received multiple courses of high-dose chemotherapy with peripheral blood stem cell support for breast cancer. Two patients had multiple febrile neutropenic episodes during this time period and each episode was analyzed separately. Seventeen Table 1 Characteristics of SCT patients with and without ototoxicity Adjusted body weight = (total body weight (kg) − ideal body weight (kg)) × 0.4 + ideal body weight.
patients (52%) received cisplatinum 165 mg/m 2 per course as part of their conditioning regimen for transplantation. The patients who experienced ototoxicity tended to be older and received gentamicin for a significantly longer duration (P = 0.001). Minimum follow-up at the time of analysis was 3 months. No patient experienced clinically detectable neuromuscular blockade.
Ototoxicity
Four patients (12%) developed clinically significant ototoxicity. All four patients had normal serum creatinine concentrations during therapy, and thus, gentamicin and vancomycin levels were not obtained. None of these patients reported prior auditory or vestibular dysfunction; however, baseline testing was not performed. One of these patients had received two courses of high-dose chemotherapy containing cisplatinum 165 mg/m 2 per course over a 2 month period. The mean duration of gentamicin therapy was 20 days (range 12-32 days) in these four patients. The mean duration of gentamicin therapy prior to the onset of symptoms was 12 days (range 3-19 days). Patients treated with SDD gentamicin for Ͼ10 days were more likely to develop ototoxicity (P = 0.045). The characteristics of ototoxicity are described in Table 2 . Ototoxicity was classified as either auditory or vestibular toxicity. Clinically significant hearing loss characterized by difficulty hearing the television and talking on the telephone occurred in four patients. Tinnitus was described by three of the four patients. Audiograms were performed on two patients and demonstrated normal middle ear function with mild to severe sensorineural loss above 1500 Hz bilaterally. One patient required bilateral hearing aids. Only one patient had reversal of symptoms upon discontinuation of gentamicin. Clinically significant vestibular toxicity occurred in two of the four patients. Symptoms included dizziness, lightheadedness with vertigo, and gait disturbance. Magnetic resonance imaging of the head was normal in both patients. One patient was unable to ambulate while the other could walk but was unable to drive due to severe dizziness. Three months after discontinuation of the drug, these symptoms had resolved.
Nephrotoxicity
One patient (3%) had doubling of their serum creatinine concentration (70-140 mol/l) during SDD gentamicin therapy which resolved when therapy was discontinued. This patient also received cyclosporine concomitantly. No other patient experienced a significant increase in serum creatinine concentration during therapy.
Discussion
Nephro-and ototoxicity are the two most common toxic effects of all aminoglycosides. 9 Previously identified risk factors for toxicity include duration of therapy, cumulative dose, previous exposure to aminoglycosides, advanced age, concurrent administration of nephrotoxins and ototoxins, and underlying disease state. The relationship between serum drug concentrations and toxicity remains controversial. Several studies have reported that monitoring of peak and trough serum aminoglycoside concentrations did not predict or prevent toxicity from occurring. [10] [11] [12] There are several scientific rationales supporting the use of SDD aminoglycosides. The bactericidal capacity of aminoglycosides is concentration-dependent. Thus, increasing the peak serum concentration should result in a more rapid and extensive bacterial kill. 13, 14 They also possess a post-antibiotic effect (PAE) which is defined as the period of suppression of bacterial growth after cessation of exposure of the bacteria to an antibiotic. The PAE is dependent in part on the presence of granulocytes and has been shown to be shorter in neutropenic mice. 15, 16 The PAE may not be as substantial in granulocytopenic patients. In addition, the clearance of aminoglycosides from serum for a period of time may reduce 'adaptive resistance' to the drug. 17 Adaptive resistance is characterized by a downregulation of drug uptake into the bacteria resulting from continuous exposure of the bacteria to antibiotic. Allowing drug levels to fall to undetectable levels with SDD regimens results in increased activity and decreased resistance.
In addition to improved efficacy, the administration of larger doses of aminoglycosides less often, as with SDD, is thought to result in decreased nephro-and ototoxicity. The accumulation of aminoglycosides by the proximal renal tubular cells and cochlear hair cells demonstrates saturable kinetics. 18, 19 Verpooten et al 20 measured renal cortical accumulation of gentamicin and netilmicin in patients undergoing elective nephrectomy. They found less drug accumulation in the renal cortex when the aminoglycoside was given as a single dose rather than the equivalent dose given as a continuous infusion over 24 h. Limiting exposure of the aminoglycoside with SDD therapy should minimize toxic effects to the ear and kidney.
Numerous studies have been published over the last several years evaluating the efficacy and toxicity of SDD vs traditional multiple daily dosing (MDD) of aminoglycosides in immunocompetent patients. Unfortunately, no single study has the statistical power to answer these questions due to the heterogeneity in patient immune status, infectious pathogen, site of infection and concurrent use of medications. At least eight meta-analyses of clinical trials comparing SDD and MDD of aminoglycosides have been published. [21] [22] [23] [24] [25] [26] [27] Unfortunately, the majority of published studies used in these meta-analyses have methodological flaws and do not permit a definitive assessment of toxicity of SDD vs MDD aminoglycosides. These flaws include small sample size, different aminoglycosides studied, variations in definitions of nephrotoxicity and ototoxicity and failure to account for concurrent use of nephro-and ototoxins. Despite the flaws in the published literature, current evidence would suggest that there is no difference in efficacy and toxicity of aminoglycoside when administered by SDD or MDD.
The reported incidence of nephrotoxicity and ototoxicity in neutropenic patients ranges from 0 to 10% and 0 to 9%, respectively. [4] [5] [6] [7] [8] We did not observe an increased incidence of nephrotoxicity in our patient population. However, clinically significant ototoxicity occurred with greater frequency (12%) than previously reported. Only one randomized, controlled trial evaluated ototoxicity in immunocompromised patients. 4 In the EORTC trial, 537 patients with cancer and granulocytopenia were randomized to receive an antimicrobial regimen containing amikacin administered either once or thrice daily. The median duration of therapy was 8 days. The incidence of nephrotoxicity was similar in both groups. Ototoxicity was determined by routine audiograms in 21% of patients evaluated. The incidence of ototoxicity in patients receiving once daily and thrice daily amikacin was 9% and 7%, respectively (P Ͼ 0.2). Only one patient experienced symptomatic hearing loss. In addition, reversible vestibular toxicity occurred in one patient receiving once daily amikacin. Most studies using SDD aminoglycoside therapy in immunocompromised patients report no clinically detectable ototoxicity. Further studies are required in immunocompromised patients to determine an accurate risk of ototoxicity associated with SDD aminoglycoside therapy.
Ototoxicity appears to depend upon not only the method of administration but also the type of aminoglycoside used. 28 In animal models gentamicin is thought to be more ototoxic than tobramycin and amikacin. 29 The use of genta-micin in our patient population may have increased the risk of ototoxicity. Concurrent use of ototoxins may have contributed to the increased incidence of ototoxicity. The patients who experienced ototoxicity had received other ototoxins. All patients had received vancomycin and three patients had received at least one other ototoxic agent. One patient had received two courses of cisplatinum, another patient had received one course of cisplatinum plus clarithromycin, and one patient received furosemide daily. The mean number of ototoxic agents administered to patients who experienced ototoxicity was 2.3 while the patients who did not experience clinically significant ototoxicity received an average of 1.6 ototoxins. The concurrent administration of ototoxic agents potentially increased the risk of ototoxicity in this subset of patients.
Advanced age is a risk factor for aminoglycosideinduced nephrotoxicity while it remains unclear whether it is a risk factor for ototoxicity. 4 A meta-analysis failed to detect a correlation between increasing age and the relative incidence of nephrotoxicity or auditory toxicity among patients receiving SDD regimens rather than MDD regimens. 26 Patients experiencing ototoxicity in our study tended to be older (53 years) than patients who did not experience this complication (41 years). Age may have played a role in the increased incidence of ototoxicity in our patients.
Lastly, the duration of therapy is a known risk factor for aminoglycoside toxicity. Although the mean duration of gentamicin therapy in our study (8 days) was similar to previous studies, the mean duration of gentamicin therapy in the patients who experienced ototoxicity (20 days) was considerably longer than in the patients who did not experience ototoxicity (9 days). Fausti et al 30 evaluated hearing loss prospectively using audiometry in 53 hospitalized patients receiving aminoglycosides. They found hearing loss occurred after a mean of 9.2 days. Patients who received SDD gentamicin for Ͼ10 days in our study were more likely to develop ototoxicity. Nicholau et al 31 described a case of irreversible ototoxicity in a patient who received a once-daily aminoglycoside for 5 weeks. Viscoli et al 8 described an increase in peak serum amikacin concentration (37-44 mg/l) in pediatric BMT patients receiving once-daily amikacin for at least 9 days. They concluded this increase represented an accumulation of the drug in deep tissue compartments, despite stable renal function. Animal studies suggest that ototoxicity is related to the total cumulative dose administered during a treatment course, and the total area under the concentration-time curve for both the plasma and perilymph. 32 Thus, the duration of aminoglycoside therapy and total cumulative dose during a treatment course rather than the SDD administration technique may have been responsible for our observed increased incidence of ototoxicity.
There are several reasons why the actual incidence of ototoxicity associated with aminoglycoside therapy remains ill defined. Patients are unlikely to complain of any hearing loss until considerable damage has occurred since hearing loss initially occurs in the high-frequency range before the low-frequency range (speech range). Bedside audiometry is not easily performed and neutropenic patients are often isolated to filtered rooms. Furthermore, there is no universally accepted definition of aminoglycoside-induced ototoxicity. 33 Vestibular testing during aminoglycoside therapy in a cancer patient is often complicated by concomitant medications which may cause similar symptoms.
A larger randomized trial involving granulocytopenic cancer patients evaluating SDD vs MDD amikacin did not detect a statistically significant difference in ototoxicity. 4 However, the median duration of therapy was only 8 days. The increased incidence of ototoxicity in our study may be due to prolonged therapy, type of aminoglycoside used, concomitant ototoxic agents, or a combination thereof. Alternatively, the small sample size may have contributed to our observations. In summary, SDD gentamicin can cause clinically significant ototoxicity. Single daily dose gentamicin should be used with caution in SCT recipients who are receiving other ototoxic agents and in patients who receive the drug for Ͼ10 days. As a result of these findings, we limited the duration of SDD aminoglycoside therapy to 7 days in SCT.
